ClinicalTrials.gg
Enrolling by invitationNCT05415800Updated Jan 20, 2025

Quality Improvement Pilot

An interventional study of Quality Improvement Practice Facilitation Intervention in Cancer, sponsored by University of Kentucky. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by University of Kentucky · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The overall goal of this study is to develop and pilot test the use of practice facilitation as an intervention for healthcare providers and staff, with the goal of improving the implementation of cancer prevention and screening guidelines in primary care settings.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Kentucky is the lead sponsor of 68 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal Volunteers

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Interventional Arm

    Intervention

    Behavioral: Quality Improvement Practice Facilitation Intervention

Interventions

  • BehavioralQuality Improvement Practice Facilitation Intervention

    The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team. The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care.

06

What researchers measure

Primary outcomes

  1. Colorectal Cancer: Screening Rate (Patient Population)

    Percent of patients age 50-75 who completed appropriate screening for colorectal cancer.

    Time frame: 6 months

  2. Lung Cancer: Screening Rate (Patient Population)

    Percent of eligible patients with shared decision-making visit AND completed baseline LDCT scan.

    Time frame: 6 months

  3. Tobacco: Treatment Rate (Patient Population)

    Percent of patients identified as tobacco user who received tobacco cessation intervention.

    Time frame: 6 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 44 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 13, 2022
StartActual
Apr 29, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05415800
Lead sponsor
University of Kentucky
Responsible party
Pamela Hull (Associate Professor, University of Kentucky) — Principal investigator
First posted
Jun 13, 2022
Start date
Apr 29, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 20, 2025

Study contacts

Pamela C Hull, PhD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion